Safety and immunogenicity of a combined DTPa–IPV vaccine administered as a booster from 4 years of age: A review
- 20 March 2006
- Vol. 24 (13) , 2440-2448
- https://doi.org/10.1016/j.vaccine.2005.12.009
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- New Pertussis Vaccination Strategies beyond Infancy: Recommendations by the Global Pertussis InitiativeClinical Infectious Diseases, 2004
- Severe and unrecognised: pertussis in UK infantsArchives of Disease in Childhood, 2003
- Immunogenicity of a Three-Component Acellular Pertussis Vaccine Administered at BirthPediatrics, 2003
- Pertussis of adults and infantsThe Lancet Infectious Diseases, 2002
- Les décès par infection bactérienne communautaire. Enquête dans les services de réanimation pédiatrique françaisArchives de Pédiatrie, 2001
- Safety and Immunogenicity of Six Acellular Pertussis Vaccines and One Whole-Cell Pertussis Vaccine Given as a Fifth Dose in Four- to Six-Year-Old ChildrenPediatrics, 2000
- Pertussis immunisation in Europe – the situation in late 1999Eurosurveillance, 2000
- Influence of vaccination coverage on pertussis transmission in FranceThe Lancet, 1999
- Changing Epidemiology of Pertussis in the United States: Increasing Reported Incidence Among Adolescents and Adults, 1990‐1996Clinical Infectious Diseases, 1999
- Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of ageThe Journal of Pediatrics, 1997